期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 108, 期 3, 页码 553-556出版社
WILEY
DOI: 10.1002/cpt.1939
关键词
-
Timely and successful drug development for rare cancer populations, such as pediatric oncology, requires consolidated efforts in the spirit of shared responsibility. In order to advance tailored development efforts, the concept of multistakeholder Strategy Forum involving industry, academia, patient organizations, and regulators has been developed. In this study, we review the first five pediatric oncology Strategy Forums co-organized by the European Medicines Agency between 2017 and 2020, reflecting on the outcomes and the evolution of the concept over time and providing an outline of how a safe space for multistakeholder engagement facilitated by regulators could be of potential value beyond pediatric oncology drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据